Exhibit 99.1 Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update · Q4 2023 YUPELRI (revefenacin) net sales, recognized by Viatris, increased 9% from Q4 2022, reaching an all-time high of $60.6 million · Full Year 2023 Viatris Collaboration Revenue increased 18% to $57.2 million · GAAP Net Loss of $8.5 million in Q4; Achieved goal of profitability on Non-GAAP basis in Q4, with Non-GAAP Net Profit of $1.4 million · Completed $325 million capital ...